Role of body composition and metabolic profile in Barrett's oesophagus and progression to cancer

被引:20
|
作者
Di Caro, Simona [1 ]
Cheung, Wui Hang [2 ,4 ]
Fini, Lucia [3 ]
Keane, Margaret G. [1 ]
Theis, Belinda [1 ]
Haidry, Rehan [1 ]
Di Renzo, Laura [2 ,4 ]
De Lorenzo, Antonino [2 ,4 ]
Lovat, Laurence [1 ]
Batterham, Rachel L. [2 ,4 ]
Banks, Matthew [1 ]
机构
[1] Univ Coll London Hosp, Dept Gastroenterol, 250 Euston Rd, London NW1 2BU, England
[2] Univ Coll London Hosp, Obes Res Ctr, Dept Med, London NW1 2BU, England
[3] Busto Arstizio Hosp, Dept Gastroenterol, Milan, Italy
[4] Tor Vergata Univ, Dept Neurosci, Rome, Italy
关键词
obesity; oesophageal cancer; Barrett's oesophagus; GASTROESOPHAGEAL-REFLUX DISEASE; CENTRAL ADIPOSITY; MASS INDEX; ABDOMINAL OBESITY; RISK-FACTORS; COLORECTAL-CANCER; BRITISH-SOCIETY; C-PEPTIDE; ASSOCIATION; PREVALENCE;
D O I
10.1097/MEG.0000000000000536
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims The aim of this study was to evaluate the risk for Barrett's oesophagus (BE) on the basis of body composition, metabolic pathways, adipokines and metabolic syndrome (MS), as well as their role in cancer progression. Methods In patients with and without BE at gastroscopy, data on MS, BMI, waist/hip ratio for abdominal obesity (AO) and body fat percentage by bioimpedance were obtained. Fasting plasma glucose, insulin, HbA1c, lipid, serum adiponectin and leptin levels were measured. The homoeostasis model assessment (HOMA-IR) was used to estimate insulin resistance. Histological findings for BE were correlated with the above parameters. Risk factors for BE identified using univariate analysis were entered into a multivariate logistic regression analysis. Results A total of 250 patients and 224 controls (F/M: 189/285, mean age 58.08 +/- 15.51 years) were enroled. In the BE and control groups, 39.6 versus 31.3% were overweight, 32 versus 22.8% were obese, 75.6 versus 51.3% had AO, and 28.1 versus 18.9% were metabolically obese, respectively. AO [odds ratio (OR) 3.08], increased body fat percentage (OR 2.29), and higher BMI (overweight: OR 2.04; obese: OR 2.26) were significantly associated with BE. A positive trend was found in Normal Weight Obese Syndrome (OR 1.69). MS was associated with BE (overweight: OR 3.05; obese: OR 5.2; AO: OR 8.08). Insulin levels (P=0.05) and HOMA-IR (P < 0.001) were higher in BE. AO was the only independent risk factor associated with BE (OR 1.65; P=0.02) and high-grade dysplasia (OR 2.44) on multivariate analysis. Conclusion AO was strongly associated with BE and dysplasia. BE was associated with MS and higher insulin/HOMA-IR, suggesting the activation of specific metabolic pathways in patients with altered body composition.
引用
收藏
页码:251 / 260
页数:10
相关论文
共 50 条
  • [41] IS SURVEILLANCE OF BARRETT'S OESOPHAGUS COST-EFFECTIVE WHEN ENDOTHERAPY IS USED TO TREAT HIGH GRADE DYSPLASIA OR EARLY CANCER IN BARRETT'S OESOPHAGUS?
    Menon, S.
    Trudgill, N.
    GUT, 2011, 60 : A35 - A35
  • [42] Frequency of the mitochondrial DNA 4977bp deletion in oesophageal mucosa during the progression of Barrett's oesophagus
    Tan, Benjamin H. L.
    Skipworth, Richard J. E.
    Stephens, Nathan A.
    Wheelhouse, Nicholas M.
    Gilmour, Hugh
    de Beauxa, Andrew C.
    Paterson-Brown, Simon
    Fearon, Kenneth C. H.
    Ross, James A.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (05) : 736 - 740
  • [43] Ablation of Barrett's oesophagus: towards improved outcomes for oesophageal cancer?
    Mayne, George C.
    Bright, Tim
    Hussey, Damian J.
    Watson, David I.
    ANZ JOURNAL OF SURGERY, 2012, 82 (09) : 592 - 598
  • [44] Human papillomavirus DNA and protein in tissue samples of oesophageal cancer, Barrett's oesophagus and oesophagitis
    Acevedo-Nuño, E
    González-Ojeda, A
    Vázquez-Camacho, G
    Ma, ABPL
    Moreno-Villa, H
    Montoya-Fuentes, H
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1319 - 1323
  • [45] Barrett's esophagus: Indicators for cancer progression
    Aust D.E.
    Baretton G.B.
    Der Gastroenterologe, 2013, 8 (6): : 487 - 494
  • [46] Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort
    Cook, Michael B.
    Coburn, Sally B.
    Lam, Jameson R.
    Taylor, Philip R.
    Schneider, Jennifer L.
    Corley, Douglas A.
    GUT, 2018, 67 (03) : 418 - 429
  • [47] Role of Acid Suppression in the Development and Progression of Dysplasia in Patients with Barrett's Esophagus
    Kastelein, F.
    Spaander, M. C. W.
    Biermann, K.
    Vucelic, B.
    Kuipers, E. J.
    Bruno, M. J.
    DIGESTIVE DISEASES, 2011, 29 (05) : 499 - 506
  • [48] Letter: is there a relationship between Barrett's oesophagus length and body mass index? Authors' reply
    Abdallah, J.
    Lewis, S.
    Fass, R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (07) : 702 - 703
  • [49] Barrett's esophagus. Indicators for cancer progression
    Aust, D. E.
    Baretton, G. B.
    GASTROENTEROLOGE, 2013, 8 (06): : 487 - 494
  • [50] Barrett's, blood groups and progression to oesophageal cancer: is nitric oxide the link?
    Caygill, Christine P. J.
    Royston, Christine
    Charlett, Andre
    Wall, Christine M.
    Gatenby, Piers A. C.
    Ramus, James R.
    Watson, Anthony
    Winslet, Marc
    Hourigan, Christopher S.
    Bardhan, Karna Dev
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (09) : 801 - 806